Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3073% below fair value
$0.18+0.00 (+0.95%)
Close on Nov 13, 2026Market cap $8.01MP/E –Yield –
Vistagen Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Vistagen Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$60.34M. For fiscal 2026 it was -$71.93M. The highest annual figure on record is -$4.97M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$71.93M | – |
| FY2025 | Mar 31, 2025 | -$55.82M | – |
| FY2024 | Mar 31, 2024 | -$32.89M | – |
| FY2023 | Mar 31, 2023 | -$59.14M | – |
| FY2022 | Mar 31, 2022 | -$47.63M | – |
| FY2021 | Mar 31, 2021 | -$17.82M | – |
| FY2020 | Mar 31, 2020 | -$20.70M | – |
| FY2019 | Mar 31, 2019 | -$24.47M | – |
| FY2018 | Mar 31, 2018 | -$14.12M | – |
| FY2017 | Mar 31, 2017 | -$10.19M | – |
| FY2016 | Mar 31, 2016 | -$17.80M | – |
| FY2015 | Mar 31, 2015 | -$6.72M | – |
| FY2014 | Mar 31, 2014 | -$4.97M | – |
| FY2013 | Mar 31, 2013 | -$6.76M | – |
| FY2012 | Mar 31, 2012 | -$9.00M | – |
| FY2011 | Mar 31, 2011 | -$6.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | -$10.89M | – |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$13.30M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$16.67M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$19.49M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$20.00M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$15.76M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$14.46M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$15.08M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$14.19M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$12.10M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$11.33M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$7.85M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$6.75M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$6.97M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$12.21M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$9.74M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$17.46M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$19.74M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$16.65M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$10.50M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$12.76M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$7.71M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$6.18M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$5.27M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$3.27M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$3.10M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$3.24M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$5.94M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$5.33M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$6.20M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$5.70M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$7.17M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$7.41M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$4.20M | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$4.06M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$2.85M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$4.97M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$2.24M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$2.53M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$2.63M | – |
See a number that looks wrong?